Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

80.8K
Overview
80.8K
Vaccinations01:51

Vaccinations

49.5K
Overview
49.5K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.3K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.3K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

86
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
86
Cancer Vaccines01:30

Cancer Vaccines

658
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
658
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

951
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
951
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Phase 1/2 Trial Of Sars-cov-2 Vaccine Chadox1 Ncov-19 With A Booster Dose Induces Multifunctional Antibody Responses.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Jordan R Barrett1, Sandra Belij-Rammerstorfer1, Christina Dold2

  • 1The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Nature Medicine
|December 18, 2020

Related Experiment Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.6K
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.3K

View abstract on PubMed

Summary
This summary is machine-generated.

A booster dose of the ChAdOx1 nCoV-19 vaccine is safe and enhances antibody responses, including neutralizing antibodies and Fc-mediated functions. This supports a two-dose vaccine regimen for severe acute respiratory syndrome coronavirus 2 prevention.

Related Experiment Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.6K
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.3K

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Over 190 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are in development.
  • Neutralizing antibodies against the spike protein are crucial, but other antibody functions may also be important for protection.
  • Previous studies reported early immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine in healthy adults.

Purpose of the Study:

  • To assess the safety and immunogenicity of a homologous booster dose of the ChAdOx1 nCoV-19 vaccine.
  • To compare full-dose and half-dose booster regimens.
  • To explore humoral and cellular immune responses following prime-boost vaccination.

Main Methods:

  • Phase 1/2 randomized controlled trial subgroups received full-dose or half-dose ChAdOx1 nCoV-19 booster vaccines 56 days post-prime.
  • Comparison with previously reported data from a 28-day interval prime-boost group and a MenACWY comparator vaccine group.
  • Systems serology was used to analyze antibody titers, Fc-mediated functions (neutrophil/monocyte phagocytosis, complement activation, NK cell activation), and T cell responses.

Main Results:

  • Booster doses of ChAdOx1 nCoV-19 were safe and better tolerated than priming doses.
  • A full-dose booster significantly enhanced anti-spike neutralizing antibody titers and Fc-mediated antibody functions compared to a half-dose boost.
  • T cell responses did not increase with either booster dose.

Conclusions:

  • A booster dose of the ChAdOx1 nCoV-19 vaccine is safe and immunogenic, substantially enhancing functional antibody responses.
  • The findings support a two-dose vaccine regimen for SARS-CoV-2 prevention.
  • Further evaluation in Phase 3 trials is warranted.